双(2-羟乙基)氨基(三羟甲基)甲烷盐酸盐 | 124763-51-5

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 双(2-羟乙基)氨基(三羟甲基)甲烷盐酸盐
• 中文别名: BIS-TRIS盐酸盐；双(2-羟基乙胺基)三(羟甲基)甲烷盐酸盐；2-[双(2-羟乙基)氨基]-2-(羟甲基)-1,3-丙二醇盐酸盐；BIS-TRIS 盐酸盐
• 英文名称: 2-(Bis(2-hydroxyethyl)amino)-2-(hydroxymethyl)propane-1,3-diol hydrochloride
• 英文别名: 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol;hydrochloride
• CAS: 124763-51-5
• 化学式: C8H20ClNO5
• 分子量: 245.7
• InChiKey: VEYRVLHAMHQVTC-UHFFFAOYSA-N

物化性质

• 密度：
  1.408 at 20℃
• LogP：
  -3.6 at 20℃ and pH5-5.3

计算性质

• 辛醇/水分配系数(LogP)：
  -2.59
• 重原子数：
  15
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  104
• 氢给体数：
  6
• 氢受体数：
  6

安全信息

• WGK Germany：
  3
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

文献信息

• [EN] HYDROGELS OF HYALURONIC ACID AND ALPHA, BETA-POLYASPARTYLHYDRAZIDE AND THEIR BIOMEDICAL AND PHARMACEUTICAL USES<br/>[FR] HYDROGELS D'ACIDE HYALURONIQUE ET DE POLYASPARTYL-HYDRAZIDE ALPHA, BETA ET LEURS UTILISATIONS PHARMACEUTIQUES ET BIOMEDICALES
  申请人：UNIV PALERMO

  公开号：WO2006001046A1

  公开（公告）日：2006-01-05

  Compositions and products based on the chemical crosslinking of hyaluronic acid with a polyfunctional polymer having a protein-like structure, bearing hydrazido pendent groups along the polymeric chain. The polymer is preferably, alpha-beta-polyaspartylhydrazide, a biocompatible macromolecule. The materials obtained after crosslinking, specifically hydrogels, undergo a reduced chemical and enzymatic degradation, unlike the starting hyaluronic acid, and they can be used to prepare systems for applications in the biomedical and pharmaceutical field.

  基于透明质酸与具有蛋白质样结构的多功能聚合物进行化学交联的组合物和产品，带有沿着聚合链的肼基侧链。该聚合物最好是α-β-聚天冬氨酸肼酸酰胺，一种生物相容性大分子。交联后获得的材料，特别是水凝胶，经历了较少的化学和酶降解，与起始的透明质酸不同，它们可以用于制备应用于生物医药领域的系统。
• Salt Form of a Multi-Arm Polymer-Drug Conjugate
  申请人：Chong Anthony O.

  公开号：US20130231359A1

  公开（公告）日：2013-09-05

  Among other aspects, provided herein is a hydrohalide salt of a multi-arm water-soluble polyethylene glycol-drug conjugate, along with related methods of making and using the same. The hydrohalide salt is stably formed, and appears to be more resistant to hydrolytic degradation than the corresponding free base form of the conjugate.

  本文提供了一种多臂水溶性聚乙二醇-药物结合物的氢卤化盐，以及相关的制备和使用方法。该氢卤化盐稳定形成，似乎比相应的自由碱基形式的结合物更抵抗水解降解。
• ACID SALT FORMS OF POLYMER-DRUG CONJUGATES AND ALKOXYLATION METHODS
  申请人：NEKTAR THERAPEUTICS

  公开号：US20150105519A1

  公开（公告）日：2015-04-16

  Among other aspects, provided herein is a mixed-acid salt of a water-soluble polymer-drug conjugate, along with related methods of making and using the same. The mixed-salt acid salt is stably formed, and appears to be more resistant to hydrolytic degradation than the corresponding predominantly pure acid salt or free base forms of the polymer-drug conjugate. The mixed acid salt is reproducibly prepared and recovered, and provides surprising advantages over non-mixed acid salt forms of the water-soluble polymer drug conjugate.

  本文提供了一种水溶性聚合物-药物共轭物的混酸盐，以及相关的制备和使用方法。该混合酸盐稳定形成，并且似乎比相应的纯酸盐或自由基形式的聚合物-药物共轭物更耐水解降解。混酸盐可重复制备和回收，并提供了比非混酸盐形式的水溶性聚合物药物共轭体更出乎意料的优势。
• ALKOXYLATION METHODS
  申请人：Nektar Therapeutics

  公开号：US20160200867A1

  公开（公告）日：2016-07-14

  Among other aspects, provided herein is a mixed-acid salt of a water-soluble polymer-drug conjugate, along with related methods of making and using the same. The mixed-salt acid salt is stably formed, and appears to be more resistant to hydrolytic degradation than the corresponding predominantly pure acid salt or free base forms of the polymer-drug conjugate. The mixed acid salt is reproducibly prepared and recovered, and provides surprising advantages over non-mixed acid salt forms of the water-soluble polymer drug conjugate.

  本文提供了一种水溶性聚合物药物结合物的混酸盐，以及相关的制备和使用方法。混酸盐稳定形成，似乎比相应的纯酸盐或游离基形式的聚合物药物结合物更具抗水解降解性。混酸盐可以被可重复地制备和回收，并且相比于水溶性聚合物药物结合物的非混酸盐形式，具有出乎意料的优势。
• Segmented degradable polymers and conjugates made therefrom
  申请人：Nektar Therapeutics

  公开号：EP2319542A2

  公开（公告）日：2011-05-11

  The present invention provides, among other things, segmented, degradable polymeric reagents suitable for reaction with biologically active agents to form conjugates, the polymeric reagents comprising one or more polymer chains divided or separated by one or more degradable linkages into polymer segments having a molecular weight suitable for renal clearance. The polymeric reagents can have a substantially linear structure, a branched structure, or a multiarm structure. Each structure includes one or more linkages capable of degradation in vivo.

  本发明除其他外提供了适合与生物活性剂反应形成共轭物的分段式可降解聚合物试剂，这些聚合物试剂由一条或多条聚合物链组成，这些聚合物链被一条或多条可降解链节分割或分离成分子量适合肾脏清除的聚合物段。聚合物试剂可具有基本线性结构、支链结构或多臂结构。每种结构都包括一种或多种可在体内降解的连接。